Evidence map›Paper›PMID 28734051›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2017

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.

Brit Mollenhauer, Richard Batrla, Omar El-Agnaf, Douglas R Galasko, Hilal A Lashuel, Kalpana M Merchant, Lesley M Shaw, Dennis J Selkoe, Robert Umek, Hugo Vanderstichele and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Cerebrospinal FluidBrain sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Brit MollenhauerParacelsus-Elena-Klinik, Kassel, Germany.
Richard BatrlaRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Omar El-AgnafNeurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), and College of Science and Engineering, HBKU, Education City, Qatar Foundation, Doha, Qatar.
Douglas R GalaskoUniversity of San Diego, San Diego, California, USA.
Hilal A LashuelLaboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Faculty of Life Science, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.
Kalpana M MerchantNorthwestern University School of Medicine, Chicago, Illinois, USA.
Lesley M ShawDepartment of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dennis J SelkoeCenter for Neurodegenerative Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Robert UmekMesoScale Discovery, Gaithersburg, Maryland, USA.
Hugo VandersticheleADx NeuroSciences, Gent, Belgium.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute, London, UK.
Jing ZhangUniversity of Washington, Seattle, Washington, USA.
Chelsea Caspell-GarciaDepartment of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
Chris CoffeyDepartment of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
Samantha J HuttenMichael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Mark FrasierMichael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Peggy TaylorBioLegend, Dedham, Massachusetts, USA.
Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
Biology of Native Alpha-Synuclein Tetramers in Parkinson's DiseaseRF1NS083845 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SELKOE, DENNIS J · 2020 to 2020
$2.9M
Biology of Native Alpha-Synuclein Tetramers in Parkinson's DiseaseR01NS083845 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SELKOE, DENNIS J · 2014 to 2018
$1.8M
NIA NIH HHS P50 AG005131NINDS NIH HHS RF1 NS083845
6 · The paper itself

Abstract

Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods. We also discuss analytical confounders. We identify gaps in the knowledge and delineate specific areas that require further investigation, such as the need to identify posttranslational modifications of α-synuclein and antibody-independent reference methods for quantification, as well as the analysis of potential confounders, such as comorbidities, medication, and phenotypes of Parkinson's disease in larger cohorts. This review could be used as a guideline for future Parkinson's disease biomarker studies and will require regular updating as more information arises in this growing field, including new technical developments as they become available. In addition to reviewing best practices, we also identify the current technical limitations and gaps in the knowledge that should be addressed to enable accurate and quantitative assessment of α-synuclein levels in the clinical setting. © 2017 International Parkinson and Movement Disorder Society.

Indexed as

alpha-SynucleinBiomarkersHumansParkinson Diseasealpha-SynucleinBiomarkersBiomarkercerebrospinal fluiddiagnosticsParkinson's diseasestandard operating proceduresα-synuclein

Identifiers

PMID28734051
PMCPMC5638072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.